# Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients

> **NCT04634435** · PHASE1 · COMPLETED · sponsor: **Biohaven Pharmaceuticals, Inc.** · enrollment: 7 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **COMBINATION_PRODUCT:** BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2

## Key facts

- **NCT ID:** NCT04634435
- **Lead sponsor:** Biohaven Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-21
- **Primary completion:** 2025-01-10
- **Final completion:** 2025-01-10
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2025-01-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04634435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04634435, "Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04634435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*